Methylene blue has a century of medical history, a legitimate mitochondrial mechanism, and real drug interaction risks that the biohacking community often downplays — here’s a balanced look at what the science actually supports.
Methylene Blue as a Mitochondrial Enhancer: Biohacking’s Favorite Industrial Dye Read More »
Exosomes are real cellular communicators with genuine therapeutic potential — but commercial longevity clinics are selling uncharacterized, unregulated products that the FDA says shouldn’t be used in humans. Here’s what the evidence actually supports.
Exosome Therapy for Longevity: Promise, Hype, and the Regulatory Wild West Read More »
Senescent ‘zombie cells’ accumulate with age and drive chronic inflammation — senolytics like fisetin, quercetin, and dasatinib are designed to clear them, with early human trial results showing real promise but significant gaps remaining.
Senolytics and Zombie Cell Clearance: Can Fisetin and Quercetin Slow Aging? Read More »
Rapamycin has extended lifespan in every major animal study that tested it, and longevity physicians are increasingly prescribing it off-label — but the human evidence is still incomplete and the immunosuppression risks are real.
BPC-157 and TB-500 are the most-discussed peptides in biohacking recovery circles — but with zero human clinical trials and a gray-market supply chain, the science is far behind the hype. Here’s what the evidence actually shows.
